Regenxbio Inc

Company Profile

Regenxbio Inc had its IPO on 2015-09-17 under the ticker symbol RGNX.

The company operates in the Healthcare sector and Biotechnology industry. Regenxbio Inc has a staff strength of 401 employees.

Stock update

Shares of Regenxbio Inc opened at $17.24 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $17.1 - $17.51, and closed at $17.32.

This is a +0.06% increase from the previous day's closing price.

A total volume of 330,366 shares were traded at the close of the day’s session.

In the last one week, shares of Regenxbio Inc have slipped by -4.47%.

Regenxbio Inc's Key Ratios

Regenxbio Inc has a market cap of $760.97 million, indicating a price to book ratio of 1.8252 and a price to sales ratio of 2.0631.

In the last 12-months Regenxbio Inc’s revenue was $96.97 million with a gross profit of $-184274000 and an EBITDA of $-250092992. The EBITDA ratio measures Regenxbio Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Regenxbio Inc’s operating margin was -274.7% while its return on assets stood at -20.35% with a return of equity of -52.91%.

In Q2, Regenxbio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 38.8%.

Regenxbio Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0.26

Its diluted EPS in the last 12-months stands at $-6.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.26. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regenxbio Inc’s profitability.

Regenxbio Inc stock is trading at a EV to sales ratio of 1.531 and a EV to EBITDA ratio of 5.9351. Its price to sales ratio in the trailing 12-months stood at 2.0631.

Regenxbio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$682.46 million

Total Liabilities

$117.89 million

Operating Cash Flow

$0

Capital Expenditure

$2.58 million

Dividend Payout Ratio

0%

Regenxbio Inc ended 2023 with $682.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $682.46 million while shareholder equity stood at $405.86 million.

Regenxbio Inc ended 2023 with $0 in deferred long-term liabilities, $117.89 million in other current liabilities, 4000.00 in common stock, $-580290000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $68.60 million and cash and short-term investments were $320.08 million. The company’s total short-term debt was $6,326,000 while long-term debt stood at $0.

Regenxbio Inc’s total current assets stands at $378.81 million while long-term investments were $95.30 million and short-term investments were $251.48 million. Its net receivables were $24.98 million compared to accounts payable of $11.64 million and inventory worth $15.11 million.

In 2023, Regenxbio Inc's operating cash flow was $0 while its capital expenditure stood at $2.58 million.

Comparatively, Regenxbio Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$17.32

52-Week High

$27.2

52-Week Low

$16.93

Analyst Target Price

$41.36

Regenxbio Inc stock is currently trading at $17.32 per share. It touched a 52-week high of $27.2 and a 52-week low of $27.2. Analysts tracking the stock have a 12-month average target price of $41.36.

Its 50-day moving average was $18.28 and 200-day moving average was $20.37 The short ratio stood at 14.43 indicating a short percent outstanding of 0%.

Around 790.8% of the company’s stock are held by insiders while 9297.5% are held by institutions.